The government is reportedly looking to increase customs duty on imported active pharmaceutical ingredients (APIs) (raw materials for medicines) by 10-15%, in order to boost local manufacturing of the bulk drugs. The Department of Pharmaceuticals (DoP) is considering an import duty of 20-25% on APIs, against the current 10%. At present, 70% of India’s API requirement is sourced from China, while for antibiotics the dependence is over 90%. India is the third largest pharma industry globally. The government is working to reduce dependency on API imports and launched an Rs 10,000 crore scheme in July to ensure adequate domestic supply.